Impact of number of lines of therapy following docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC).

被引：1
|
作者：
Sonpavde, Guru
Bhor, Menaka
Hennessy, Daniel
Bhowmik, Debajyoti
Shen, Liji
Schnadig, Ian D.
机构：
[1] UAB Comprehens Canc Ctr, Birmingham, AL USA
[2] McKesson Specialty Hlth, The Woodlands, TX USA
[3] US Oncol Network, The Woodlands, TX USA
[4] Sanofi Aventis, Bridgewater, NJ USA
[5] Compass Oncol, Portland, OR USA
[6] US Oncol Network, Portland, OR USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.223
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
223
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
    Bracarda, S.
    Sisani, M.
    Rossi, M.
    Galli, L.
    Hamzaj, A.
    Scali, S.
    De Angelis, V.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Schnadig, Ian D.
    Bhor, Menaka
    Vogelzang, Nicholas J.
    Hennessy, Daniel
    Nicacio, Leonardo V.
    Berry, William R.
    Hutson, Thomas E.
    Fleming, Mark T.
    Cowey, C. Lance
    Saravanan, Shanmugapriya
    Dhanda, Rahul
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [3] INTERMITTENT (RECHALLENGE) CHEMOTHERAPY WITH DOCETAXEL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Bracarda, Sergio
    Rossi, Marta
    Hamzaj, Alketa
    De Angelis, Verena
    De Simone, Valeria
    Caserta, Claudia
    Crino, Lucio
    ANNALS OF ONCOLOGY, 2009, 20
  • [4] Management of metastatic castration-resistant prostate cancer following docetaxel
    Beuzeboc, Philippe
    Ropert, Stanislas
    Goldwasser, Francois
    Zerbib, Marc
    BULLETIN DU CANCER, 2012, 99 : S66 - S72
  • [5] Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael Thomas
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [6] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Bilusic, Marijo
    Karzai, Fatima
    Cordes, Lisa M.
    Strauss, Julius
    Schlom, Jeffrey
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Karzai, Fatima
    Cordes, Lisa M.
    Schlom, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [8] Response to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) poorly responding to docetaxel
    Angelergues, A.
    Bellmunt, J.
    Efstathiou, E.
    Gonzalez, I.
    Gyftaki, R.
    Delanoy, N.
    Ozguroglu, M.
    Flechon, A.
    Guillot, A.
    Le Moulec, S.
    Castellano, D.
    Esteban, E.
    Munarriz, J.
    Campos Balea, B.
    Ardavanis, A.
    Stefanou, D.
    Oudard, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S488 - S488
  • [9] Docetaxel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC): an Observational Study in a Single Institution
    Schallier, D.
    Decoster, L.
    Braeckman, J.
    Fontaine, C.
    Degreve, J.
    ANTICANCER RESEARCH, 2012, 32 (02) : 633 - 641
  • [10] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Baciarello, Giulia
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
12345